Bioregenx (BRGX) Liabilities and Shareholders Equity (2021 - 2026)

Bioregenx's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $337070.0 for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 30.16% year-over-year to $337070.0 in Q1 2026; TTM through Mar 2026 was $3.1 million, a 91.54% decrease from a year earlier, with the FY2025 full-year figure at $410986.0, down 19.18% from the prior year.
• Liabilities and Shareholders Equity retreated to $337070.0 in Q1 2026 per BRGX's latest filing, from $410986.0 in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $18.6 million in Q1 2024 and bottomed at $33981.0 in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $495579.0 (2024), against an average of $4.2 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 50991.39% in 2024 and plunged 97.41% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $59149.0 in 2022, then jumped by 1363.68% to $865750.0 in 2023, then tumbled by 41.26% to $508535.0 in 2024, then declined by 19.18% to $410986.0 in 2025, then decreased by 17.99% to $337070.0 in 2026.
• Per Business Quant, the three latest BRGX Liabilities and Shareholders Equity figures stand at $337070.0 (Q1 2026), $410986.0 (Q4 2025), and $1.2 million (Q3 2025).